UBS analyst Danielle Antalffy remains bullish on Inspire Medical (INSP), and sees Eli Lilly’s (LLY) top-line SURMOUNT-OSA readout as right in line with expectations for apnea-hypopnea index reduction and the removal of an overhang. While the results likely support labeling for tirzepatide in treatment of obstructive sleep apnea, UBS does not see a near-term or even mid- to-long impact to Inspire fundamentals and sees any share weakness as a good buying opportunity, the analyst tells investors in a research note. UBS made no change to its Buy rating or $265 price target on Inspire Medical.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical Systems, Inc. to Report First Quarter 2024 Financial Results on May 7, 2024
- LivaNova jumps nearly 12% after saying trial likely to meet primary endpoint
- Snowflake, MongoDB downgraded to Sell: Wall Street’s top analyst calls
- Inspire Medical initiated with an Overweight at Morgan Stanley
- Inspire Medical Systems, Inc. to Present at the KeyBanc Life Sciences & MedTech Investor Forum